Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 2
1962 4
1963 5
1964 9
1965 8
1966 6
1967 10
1968 5
1969 7
1970 10
1971 15
1972 11
1973 13
1974 4
1975 10
1976 13
1977 9
1978 12
1979 12
1980 15
1981 15
1982 14
1983 14
1984 12
1985 13
1986 17
1987 19
1988 13
1989 20
1990 12
1991 17
1992 17
1993 23
1994 18
1995 15
1996 12
1997 24
1998 23
1999 23
2000 16
2001 17
2002 18
2003 12
2004 13
2005 6
2006 17
2007 8
2008 8
2009 18
2010 5
2011 6
2012 13
2013 7
2014 9
2015 10
2016 8
2017 5
2018 8
2019 8
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

711 results

Results by year

Filters applied: . Clear all
Page 1
MTHFD2--a new twist?
Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR. Tedeschi PM, et al. Among authors: bertino jr. Oncotarget. 2016 Feb 16;7(7):7368-9. doi: 10.18632/oncotarget.7147. Oncotarget. 2016. PMID: 26848977 Free PMC article. No abstract available.
In cancer, all roads lead to NADPH.
Rather GM, Pramono AA, Szekely Z, Bertino JR, Tedeschi PM. Rather GM, et al. Among authors: bertino jr. Pharmacol Ther. 2021 Oct;226:107864. doi: 10.1016/j.pharmthera.2021.107864. Epub 2021 Apr 22. Pharmacol Ther. 2021. PMID: 33894275 Review.
Exploiting methionine restriction for cancer treatment.
Chaturvedi S, Hoffman RM, Bertino JR. Chaturvedi S, et al. Among authors: bertino jr. Biochem Pharmacol. 2018 Aug;154:170-173. doi: 10.1016/j.bcp.2018.05.003. Epub 2018 May 4. Biochem Pharmacol. 2018. PMID: 29733806 Review.
Leucovorin rescue revisited.
Bertino JR. Bertino JR. J Clin Oncol. 1990 Feb;8(2):193-5. doi: 10.1200/JCO.1990.8.2.193. J Clin Oncol. 1990. PMID: 2299365 No abstract available.
The clopidogrel conundrum.
Bertino JS Jr. Bertino JS Jr. J Clin Pharmacol. 2014 Aug;54(8):841-2. doi: 10.1002/jcph.344. J Clin Pharmacol. 2014. PMID: 25044099 No abstract available.
The safety profile of the fluoroquinolones.
Bertino J Jr, Fish D. Bertino J Jr, et al. Clin Ther. 2000 Jul;22(7):798-817; discussion 797. doi: 10.1016/S0149-2918(00)80053-3. Clin Ther. 2000. PMID: 10945507 Review.
NAD+ Kinase as a Therapeutic Target in Cancer.
Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR. Tedeschi PM, et al. Among authors: bertino jr. Clin Cancer Res. 2016 Nov 1;22(21):5189-5195. doi: 10.1158/1078-0432.CCR-16-1129. Epub 2016 Aug 31. Clin Cancer Res. 2016. PMID: 27582489 Review.
Resistance mechanisms to methotrexate in tumors.
Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Bertino JR, et al. Stem Cells. 1996 Jan;14(1):5-9. doi: 10.1002/stem.140005. Stem Cells. 1996. PMID: 8820944 Review.
Dihydrofolate reductase as a therapeutic target.
Schweitzer BI, Dicker AP, Bertino JR. Schweitzer BI, et al. Among authors: bertino jr. FASEB J. 1990 May;4(8):2441-52. doi: 10.1096/fasebj.4.8.2185970. FASEB J. 1990. PMID: 2185970 Review.
711 results